Sign in
SCHEDULE 13G/A

Statement of Beneficial Ownership

Maze Therapeutics, Inc. Filed Acc 0001193125-26-463548

Stakes reported in this filing

Reporting person Shares Of the class
Third Rock Ventures IV, L.P. 3,723,958 6.7%
Third Rock Ventures GP IV, L.P. 3,723,958 6.7%
TRV GP IV, LLC 3,723,958 6.7%
Third Rock Ventures V, L.P. 950,800 1.7%
Third Rock Ventures GP V, L.P. 950,800 1.7%
TRV GP V, LLC 950,800 1.7%

Members of a group can each report the same shares, so these rows overlap and don't add up.

Loading xslSCHEDULE_13G_X02/primary_doc.xml…